The kidney is highly susceptible to radiopharmaceutical toxicity. Its high blood flow, metabolic activity and transporters trap tracers and metabolites in proximal tubule cells, often causing dose-limiting nephrotoxicity that hinders clinical translation. At Protheragen, we deliver comprehensive in vitro nephrotoxicity screening services that leverage physiologically relevant human renal cell models, validated biomarker panels, and advanced culture platforms to evaluate the kidney toxicity potential of your radiopharmaceutical candidates early in development, enabling data-driven formulation optimization and regulatory-compliant safety assessment.
Nephrotoxicity is a major dose-limiting side effect of radiopharmaceuticals. The kidney's high blood perfusion and powerful tubular transporters massively enrich tracers and metabolites inside proximal tubule cells, whose abundant mitochondria also make them prone to oxidative stress. Kidney damage stems from retained radioactivity, toxic chelator/vector backbones, or harmful radiolytic metabolites, triggering acute tubular necrosis or chronic interstitial fibrosis. Conventional markers like creatinine and BUN lack sensitivity and only detect severe renal damage late in development, making dedicated preclinical nephrotoxicity testing indispensable. Different radionuclides and chelator structures greatly alter renal accumulation levels, leading to large differences in kidney injury risk across radiotheranostic candidates. Early sensitive renal biomarkers are required to spot mild tubular lesions before irreversible nephron loss emerges.
Fig 1. Workflow diagram of development of multiregion kidney model. (Zhang, Siqi, et al., 2025)
| Platform/Biomarker | Primary Applications in Radiopharmaceutical R&D |
|---|---|
| 2D Proximal Tubule Cell Lines (ciPTEC, RPTEC/TERT1) | Early-stage radiopharmaceutical uptake and retention screening; transporter-mediated toxicity assessment; structure-toxicity relationship studies; kidney protection strategy evaluation. |
| Primary Human Proximal Tubule Cells (hPTEC) | Late-stage validation of in vitro predictions; mechanistic studies of radiopharmaceutical uptake pathways; personalized toxicity risk assessment. |
| 3D Kidney Organoids | Segment-specific nephrotoxicity assessment (proximal, distal, collecting duct); evaluation of radiopharmaceutical penetration into tubular structures; chronic toxicity modeling. |
| Kidney-on-Chip Microfluidic Systems | Dynamic radiopharmaceutical uptake and clearance studies; evaluation of flow-dependent toxicity; multi-organ interaction modeling (liver-kidney coupling). |
| KIM-1 (Kidney Injury Molecule-1) | Early detection of radiopharmaceutical-induced proximal tubule damage; monitoring of kidney protection strategy efficacy; regulatory-compliant safety endpoint. |
| NGAL (Neutrophil Gelatinase-Associated Lipocalin) | Early AKI detection following radiopharmaceutical administration; prognostic indicator for renal recovery; combination biomarker panel component. |
| Clusterin | Monitoring of sublethal radiopharmaceutical-induced tubular stress; assessment of recovery potential; combination with KIM-1 for enhanced specificity. |
| Cystatin C & β2-Microglobulin | Assessment of glomerular vs. tubular radiopharmaceutical toxicity; monitoring of renal function decline; regulatory-qualified preclinical endpoint. |
Protheragen offers a comprehensive suite of in vitro nephrotoxicity screening services specifically designed for radiopharmaceutical preclinical development, integrating physiologically relevant human renal cell models, validated biomarker panels, and advanced culture platforms to deliver robust, predictive kidney safety data. Our capabilities span conditionally immortalized proximal tubule cell lines with functional transporter expression, primary human renal cell assays, 3D kidney organoid systems, and kidney-on-chip microfluidic platforms, complemented by a full panel of qualified biomarkers including KIM-1, NGAL, clusterin, and cystatin C.
We use polarized human renal cell lines (ciPTEC, RPTEC/TERT1) with intact transporters and megalin-cubilin receptors to test radiopharmaceutical renal uptake and retention. Gamma counting tracks intracellular tracer accumulation over time; transporter inhibitors and gene knockdowns clarify uptake pathways (transporter transport, diffusion, endocytosis). Washout retention tests screen agents prone to long-term tubular trapping and high nephrotoxic risk, guiding chelator and vector structural optimization to cut renal uptake while keeping tumor affinity.
This multiplex panel detects early subtle tubular injury via regulatory-validated markers (KIM-1, NGAL, clusterin etc.) with ELISA, qPCR and high-throughput immunoassays. Tested across serial concentrations with positive injury controls, biomarkers identify damage much earlier than conventional LDH and ATP readouts. Quantitative data ranks compound renal risk, defines NOAEL values and supports regulatory documentation.
Transwell renal cell models measure radiopharmaceutical inhibition of OAT, OCT, MDR and MATE transporters using probe substrates, calculating transporter IC50 to judge clinical DDI risk. We test protective co-drugs to block tubular uptake without hurting tumor binding, and build kinetic models to predict in vivo clearance shifts, critical for repeated or combination radiopharmaceutical regimens.
Proximal tubules rely heavily on mitochondria; we use galactose shift assay, Seahorse flux, JC-1 and mitochondrial staining to detect mitochondrial dysfunction. DCFH-DA quantifies ROS, while antioxidant rescue experiments verify oxidative damage pathways. Side-by-side radiolabeled and cold analog testing separates radiation-induced vs ligand-driven mitochondrial injury, supporting antioxidant or chelator modification to lower renal oxidative toxicity.
Human stem cell-derived kidney organoids replicate tubular, glomerular and endothelial structures for physiologically relevant toxicity testing, analyzed via immunofluorescence, live/dead staining and biomarker detection. Perfusable kidney-on-chip microfluidics mimic physiological flow and track TEER and permeability in real time. These 3D systems reveal segment-specific and chronic low-dose renal injury, bridging 2D monolayer and animal study data.
We test multiple nephroprotective approaches including amino acid competitive blockers, gelatin expanders, pH-modified formulations and antioxidants on renal cell platforms. Head-to-head comparisons measure tracer uptake, retention and injury biomarker levels, while parallel tumor cell assays confirm anti-tumor activity remains intact. Quantitative in vitro data delivers actionable clinical guidance on optimal protective regimens.
Whether you are screening a series of radiolabeled peptides for renal uptake liability, evaluating the nephrotoxicity potential of a novel alpha-emitter conjugate, or seeking to validate kidney protection strategies for your PRRT clinical trial design, Protheragen is ready to design and execute an in vitro nephrotoxicity screening program that meets your scientific and regulatory objectives. Reach out to our team of nephrotoxicology and radiochemistry specialists to discuss your compound properties, anticipated renal handling pathway, and development stage. Contact us today to schedule a consultation and discover how our in vitro nephrotoxicity screening services can provide the kidney safety data your radiopharmaceutical development program demands.
Reference